Skip to main
ACET
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 71%
Buy 21%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc. is advancing its clinical-stage pipeline, particularly with its lead product candidate, ADI-001, which has received FDA Fast Track Designation for systemic sclerosis treatment and shows promising results in B-cell depletion for non-Hodgkin’s lymphoma. The preclinical candidate ADI-270 demonstrates stronger anti-tumor activity compared to traditional αβ CAR-T cells and has a potential risk-benefit profile beneficial for renal cell carcinoma and other indications. Financially, Adicet maintains a solid cash position of $176.3 million, which supports further development and exploration of its innovative therapies.

Bears say

Adicet Bio Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to a lack of differentiating clinical data for its therapies and the potential approval of competitive products, which could severely limit sales potential. The company reported R&D expenses of $23.3 million, which were lower than expected, but ongoing regulatory and competitive risks remain a concern, as the majority of drugs in clinical development fail to reach the market. Additionally, despite an ending cash balance of $176.3 million, the stock price may decline even if the company meets or exceeds investor expectations, highlighting the volatility and uncertainty surrounding its future financial performance.

ACET has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 21% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 14 analysts, ACET has a Strong Buy consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.